• On 19 May 2026, Rubrik and MEDITECH announced a collaboration to embed Rubrik Security Cloud into MEDITECH Expanse, bringing immutable data protection, threat monitoring, rapid recovery, and cloud archival to healthcare providers across self-hosted cloud and on-premises environments.
• This move directly targets rising ransomware risk in healthcare by offering hospitals a unified control plane to keep critical systems running and patient care uninterrupted, regardless of where their data resides.
• Next, we’ll examine how this MEDITECH Expanse integration, especially its focus on immutable healthcare data protection, may reshape Rubrik’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 47 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Rubrik Investment Narrative Recap

To own Rubrik, you need to believe its focus on cyber resilience can justify a rich valuation despite ongoing losses and heavy reinvestment. The MEDITECH Expanse integration reinforces the core ransomware protection story in healthcare, but does not meaningfully change the near term tension between strong topline growth expectations and the key risk of sustained unprofitability and cash flow pressure.

Among recent developments, the American Hospital Association’s Preferred Cybersecurity Provider designation in March 2026 looks especially relevant. Together with the MEDITECH collaboration, it underlines Rubrik’s growing presence in healthcare, a sector where ransomware risk is acute and operational continuity is critical, potentially supporting its data security catalyst while competition and pricing pressure remain important watchpoints.

Yet against this promise, the risk that rising cyber threats force higher ongoing spend and keep Rubrik’s margins under pressure is something investors should be aware of...

Rubrik's narrative projects $2.4 billion revenue and $276.6 million earnings by 2029. This requires 21.5% yearly revenue growth and a $625.4 million earnings increase from -$348.8 million today.

Uncover how Rubrik's forecasts yield a $84.07 fair value, a 28% upside to its current price.

Exploring Other Perspectives

Before this MEDITECH news, the most pessimistic analysts still expected about 24.3% annual revenue growth to roughly US$2.3 billion by 2029, but they worried that heavier reinvestment to keep up with advanced cyber threats could cap margins and keep profits elusive, showing how differently you and other investors might view Rubrik’s path from here.

Explore 11 other fair value estimates on Rubrik - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Rubrik research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Rubrik research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rubrik's overall financial health at a glance.

Ready For A Different Approach?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• Find 47 companies with promising cash flow potential yet trading below their fair value.
• Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.